Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1973 1
1976 1
1979 2
1980 1
1981 3
1984 5
1985 7
1986 4
1987 4
1988 14
1989 27
1990 25
1991 22
1992 29
1993 44
1994 35
1995 35
1996 57
1997 46
1998 73
1999 60
2000 61
2001 82
2002 70
2003 84
2004 82
2005 120
2006 107
2007 157
2008 140
2009 174
2010 174
2011 195
2012 220
2013 244
2014 232
2015 252
2016 253
2017 268
2018 261
2019 298
2020 338
2021 273
2022 252
2023 215
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

4,680 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Immunodeficiency 64"
Page 1
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Craig TJ, et al. Lancet. 2023 Apr 1;401(10382):1079-1090. doi: 10.1016/S0140-6736(23)00350-1. Epub 2023 Feb 28. Lancet. 2023. PMID: 36868261 Clinical Trial.
The randomisation list and code were kept by the IRT provider during the study, with no access by site staff and funding representatives. ...Of 65 eligible patients with type I or type II hereditary angioedema, 39 were randomly assigned to garadacimab and 26 to plac …
The randomisation list and code were kept by the IRT provider during the study, with no access by site staff and funding representati …
Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
Sim B, Ng JY, Teh BW, Talaulikar D. Sim B, et al. Leuk Lymphoma. 2023 Jan;64(1):18-29. doi: 10.1080/10428194.2022.2131424. Epub 2022 Oct 11. Leuk Lymphoma. 2023. PMID: 36218218
Acquired hypogammaglobulinemia or secondary immunodeficiency (SID) occurs commonly in hematological malignancies with increasing incidence and complexity in the era of modern therapies. ...Dosing and indications for cessation of IgRT are also inadequately characterized. Fu …
Acquired hypogammaglobulinemia or secondary immunodeficiency (SID) occurs commonly in hematological malignancies with increasing inci …
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. Bucher HC, et al. J Clin Epidemiol. 1997 Jun;50(6):683-91. doi: 10.1016/s0895-4356(97)00049-8. J Clin Epidemiol. 1997. PMID: 9250266
We present an alternative model that evaluates the differences between treatment and placebo in two sets of clinical trials, and preserves the randomization of the originally assigned patient groups. ...The indirect comparison showed substantial increased benefit fr …
We present an alternative model that evaluates the differences between treatment and placebo in two sets of clinical trials, and pres …
Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
Cuvelier GDE, Logan BR, Prockop SE, Buckley RH, Kuo CY, Griffith LM, Liu X, Yip A, Hershfield MS, Ayoub PG, Moore TB, Dorsey MJ, O'Reilly RJ, Kapoor N, Pai SY, Kapadia M, Ebens CL, Forbes Satter LR, Burroughs LM, Petrovic A, Chellapandian D, Heimall J, Shyr DC, Rayes A, Bednarski JJ, Chandra S, Chandrakasan S, Gillio AP, Madden L, Quigg TC, Caywood EH, Dávila Saldaña BJ, DeSantes K, Eissa H, Goldman FD, Rozmus J, Shah AJ, Vander Lugt MT, Thakar MS, Parrott RE, Martinez C, Leiding JW, Torgerson TR, Pulsipher MA, Notarangelo LD, Cowan MJ, Dvorak CC, Haddad E, Puck JM, Kohn DB. Cuvelier GDE, et al. Blood. 2022 Aug 18;140(7):685-705. doi: 10.1182/blood.2022016196. Blood. 2022. PMID: 35671392 Free PMC article. Clinical Trial.
Adenosine deaminase (ADA) deficiency causes 13% of cases of severe combined immune deficiency (SCID). ...We evaluated 131 patients with ADA-SCID diagnosed between 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID studi …
Adenosine deaminase (ADA) deficiency causes 13% of cases of severe combined immune deficiency (SCID). ...We evaluated 131 pati …
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples.
Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Anglemyer A, et al. Cochrane Database Syst Rev. 2013 Apr 30;4(4):CD009153. doi: 10.1002/14651858.CD009153.pub3. Cochrane Database Syst Rev. 2013. PMID: 23633367 Free PMC article. Review.
BACKGROUND: Antiretroviral drugs have been shown to reduce risk of mother-to-child transmission of human immunodeficiency virus (HIV) and are also widely used for post-exposure prophylaxis for parenteral and sexual exposures. ...These ten studies identified 2,112 episodes …
BACKGROUND: Antiretroviral drugs have been shown to reduce risk of mother-to-child transmission of human immunodeficiency virus (HIV) …
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Penazzato M, Dominguez K, Cotton M, Barlow-Mosha L, Ford N. Penazzato M, et al. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S177-81. doi: 10.1093/cid/civ110. Clin Infect Dis. 2015. PMID: 25972500 Review.
The proportion of children completing the full 28-day course of PEP was 64.0% (95% confidence interval [CI], 41.2%-86.8%), whereas the proportion discontinuing due to adverse events was 4.5% (95% CI, .4%-8.6%). One randomized trial compared abacavir (ABC) plu …
The proportion of children completing the full 28-day course of PEP was 64.0% (95% confidence interval [CI], 41.2%-86.8%), whereas th …
Utilisation of immunoglobulin in New Zealand.
Mishra S, Flanagan P, Frampton C. Mishra S, et al. Intern Med J. 2023 Jun;53(6):1032-1041. doi: 10.1111/imj.15694. Epub 2022 Aug 31. Intern Med J. 2023. PMID: 35049107
BACKGROUND: Immunoglobulin is an expensive and scarce resource and usage is increasing worldwide. Immunoglobulin is used to treat a variety of clinical conditions, particularly primary and acquired immunodeficiencies and immune-mediated neurological disorders. ...AI …
BACKGROUND: Immunoglobulin is an expensive and scarce resource and usage is increasing worldwide. Immunoglobulin is used to treat a variety …
Pediatric Human Immunodeficiency Virus Continuum of Care: A Concise Review of Evidence-Based Practice.
Gray ME, Nieburg P, Dillingham R. Gray ME, et al. Pediatr Clin North Am. 2017 Aug;64(4):879-891. doi: 10.1016/j.pcl.2017.03.009. Pediatr Clin North Am. 2017. PMID: 28734516 Free PMC article. Review.
Children and adolescents living with human immunodeficiency virus (HIV) represent a population that requires a unique approach to HIV care. ...
Children and adolescents living with human immunodeficiency virus (HIV) represent a population that requires a unique approach to HIV …
Factors influencing treatment adherence in hypertension and HIV management in South Africa: A comparative literature review.
Enslin D, Mallya P. Enslin D, et al. S Afr Fam Pract (2004). 2022 Jun 29;64(1):e1-e10. doi: 10.4102/safp.v64i1.5434. S Afr Fam Pract (2004). 2022. PMID: 36073101 Free PMC article. Review.
BACKGROUND: Hypertension (HTN) is the most significant risk factor for cardiovascular disease (CVD) in South Africa (SA), with one in three people over the age of 25 suffering from HTN. Whilst human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/ …
BACKGROUND: Hypertension (HTN) is the most significant risk factor for cardiovascular disease (CVD) in South Africa (SA), with one in three …
Interventions for improving health literacy in migrants.
Baumeister A, Aldin A, Chakraverty D, Hübner C, Adams A, Monsef I, Skoetz N, Kalbe E, Woopen C. Baumeister A, et al. Cochrane Database Syst Rev. 2023 Nov 14;11(11):CD013303. doi: 10.1002/14651858.CD013303.pub2. Cochrane Database Syst Rev. 2023. PMID: 37963101 Review.
SEARCH METHODS: We ran electronic searches to 2 February 2022 in CENTRAL, MEDLINE, Embase, PsycInfo and CINAHL. We also searched trial registries. We used a study filter for randomised controlled trials (RCTs) (RCT classifier). ...Compared with written information o …
SEARCH METHODS: We ran electronic searches to 2 February 2022 in CENTRAL, MEDLINE, Embase, PsycInfo and CINAHL. We also searched trial …
4,680 results